WCN25-1879 LUTETIUM IN THE TREATMENT OF METASTATIC NEUROENDOCRINE TUMOUR IN A PATIENT ON MAINTENANCE HEMODIALYSIS - A CASE REPORT
Neuroendocrine tumours (NET) arise from neuroendocrine cells with an incidence of 2 per 1,00,000 general population (0.5% of all malignancies). Radio ligand therapy (aka Peptide Receptor Radionuclide Therapy) with 177Lutetium-dotatate is a documented safe and effective treatment in metastatic NET. Bone marrow suppression and renal impairment are the dose limiting adverse effects.
Authors
- Dinesh Kannabhiran (ORCID: https://orcid.org/0000-0003-1686-827X)
- Rajan Ravichandran
- A Kanakaraj
- Priyanka Bathrinarayanan
- Satish Nath SD
Institutions
- Madras Institute of Orthopaedics and Traumatology (IN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.217
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35